Stockscreener 앱 받기
3.35
4.36%
0.14
시간 외 거래:
3.35
전일 마감가:
$3.21
열려 있는:
$3.3
하루 거래량:
15,950
Relative Volume:
0.60
시가총액:
$6.44M
수익:
$6.50M
순이익/손실:
$-29.58M
주가수익비율:
-0.2051
EPS:
-16.3362
순현금흐름:
$-34.58M
1주 성능:
-17.28%
1개월 성능:
-17.28%
6개월 성능:
-32.32%
1년 성능:
-38.42%
1일 변동 폭
$3.20
$3.35
1주일 범위
$3.13
$4.0817
52주 변동 폭
$3.13
$7.1999
볼트 바이오테라퓨틱스 Stock (BOLT) Company Profile
명칭
Bolt Biotherapeutics Inc
전화
650-665-9295
주소
900 CHESAPEAKE DRIVE, REDWOOD CITY
Compare BOLT vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BOLT
Bolt Biotherapeutics Inc
|
3.35 | 6.63M | 6.50M | -29.58M | -34.58M | -16.34 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
볼트 바이오테라퓨틱스 Stock (BOLT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 재개 | H.C. Wainwright | Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-03-02 | 개시 | Guggenheim | Buy |
| 2021-03-02 | 개시 | Morgan Stanley | Overweight |
| 2021-03-02 | 개시 | SVB Leerink | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
모두보기
볼트 바이오테라퓨틱스 주식(BOLT)의 최신 뉴스
Renaissance Technologies (BOLT) reports 5.13% ownership stake in Bolt Biotherapeutics - Stock Titan
Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates - Yahoo! Finance Canada
BOLT Looks 49.0% Undervalued on GF Value™ Despite Clinical-Stage Challenges - GuruFocus
Bolt Biotherapeutics Inc.: Q2 Earnings Snapshot - KVUE
Bolt Biotherapeutics Q2 net loss narrows on restructuring and lower research activity - TradingView
Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Bolt Biotherapeutics, Inc. Q2 2026: Revenue $5K, Net loss $(7.72M), EPS $(4.57) — 10-Q Summary - TradingView
Bolt Biotherapeutics (BOLT) flags going concern risk as losses fall and cash nears $18M - Stock Titan
Bolt Biotherapeutics' Cancer Trial Data Expected With Q3 Results - Stock Titan
Bolt Biotherapeutics (BOLT) Advances 4.65% as Buyers Defend Key SupportSymmetrical Triangle - dars.gov.et
Bolt Biotherapeutics Inc (BOLT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BOLT Q2'26 Earnings: revenue estimate is 500.00K USD - TradingView
Bolt Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:BOLT - TradingView
Bolt Biotherapeutics Inc (BOLT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bolt Biotherapeutics Inc (BOLT) Valuation: PE, PB & Fair Value Analysis - tradingkey.com
Bolt Biotherapeutics Inc (BOLT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Bolt Biotherapeutics Inc (BOLT) Cash Flow - TradingKey
BOLT|Bolt Biotherapeutics Inc|Price:3.830|Chg%:+0.110 - TradingKey
Bolt Biotherapeutics Inc (BOLT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bolt Biotherapeutics Inc. (BOLT) Q1 2026 Earnings: Wider-than-Expected Loss Amid Clinical Development ProgressAnalyst Consensus Shift - dars.gov.et
Bolt Biotherapeutics Inc. (BOLT) Q1 2026 Earnings: Wider-than-Expected Loss as Development Stage Company Reports No RevenueROE Trend Analysis - dars.gov.et
Bolt Biotherapeutics (BOLT) Gains Momentum: Stock Rises 1.82% Amid Potential Biotech RallyZigzag Correction - dars.gov.et
Bolt Biotherapeutics Inc (BOLT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
A419U9 Forecast — Price Target — Prediction for 2027 - TradingView
BOLT Forecast — Price Target — Prediction for 2027 - TradingView
Bolt Biotherapeutics, Inc. Actuals & Estimates (MUN:6LP0) - TradingView
Enterprise value to revenue forward of Bolt Biotherapeutics, Inc. – NASDAQ:BOLT - TradingView
Revenue per share of Bolt Biotherapeutics, Inc. – FWB:6LP0 - TradingView
6LP0 Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Bolt Biotherapeutics, Inc. – NASDAQ:BOLT - TradingView
Bolt Biotherapeutics (BOLT) Slides 5% in Heavy Trading as Key Support Level ApproachesVOLD Alert - dars.gov.et
Bolt Biotherapeutics Inc (BOLT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bolt Biotherapeutics Inc (BOLT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bolt Biotherapeutics Inc (BOLT) Institutional Confidence - TradingKey
Bolt Biotherapeutics Inc. (BOLT) Q1 2026 Earnings: Large EPS Miss Reflects Continued R&D InvestmentEPS Growth Rate - newsline.com
Bolt Biotherapeutics Holds 2026 Annual Stockholder Meeting - TipRanks
Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 exercise price - Stock Titan
Bolt Biotherapeutics (NASDAQ: BOLT) grants director options for 5,000 shares - Stock Titan
Bolt Biotherapeutics (NASDAQ: BOLT) director receives 5,000-share stock option grant - Stock Titan
Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 strike price - Stock Titan
Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 strike - Stock Titan
Bolt Biotherapeutics (BOLT) Dips 2.33% as Biotech Sector Headwinds PersistVolatility Stop - DonanımHaber
Bolt Biotherapeutics (BOLT) Declines Over 4%, Nears Critical Support LevelFade Trade - po-news-eg.net
Bolt Biotherapeutics (BOLT) Slides 4% Amid Biotech Sector Turbulence – Key Levels to WatchDark Pool Sentiment - dars.gov.et
BOLT Q1 2026 Earnings: Deep EPS Miss Highlights Operational ChallengesPost-Earnings Drift - newsline.com
Bolt Biotherapeutics Price Target Announced at $22.00/Share by Rodman & Renshaw - Moomoo
BOLT Initiates Coverage On Rodman & Renshaw -- Rating Set to Buy - GuruFocus
Rodman & Renshaw initiates Bolt Biotherapeutics stock with buy rating By Investing.com - Investing.com Nigeria
Bolt Biotherapeutics (BOLT) Gains 2.32%: Biotech Stock Approaches Key Resistance LevelIchimoku Kumo Twist - The Legal Advocate
Rodman & Renshaw initiates Bolt Biotherapeutics stock with buy rating - Investing.com
볼트 바이오테라퓨틱스 (BOLT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):